Cyramza Prices, Coupons, Copay Cards & Patient Assistance
Cyramza (ramucirumab) is a member of the VEGF/VEGFR inhibitors drug class and is commonly used for Colorectal Cancer, Gastric Cancer, Hepatocellular Carcinoma, and others.
The cost for Cyramza (10 mg/mL) intravenous solution is around $1,581 for a supply of 10 milliliters, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Cyramza prices
Intravenous Solution
10 mg/mL
Cyramza intravenous solution
from $1,580.70
for 10 milliliters
Quantity | Per unit | Price |
---|---|---|
10 milliliters | $158.07 | $1,580.70 |
50 milliliters | $157.27 | $7,863.52 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Cyramza Coupons, Copay Cards and Rebates
Cyramza offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Cyramza Savings Card
Eligible commercially insured patients may pay as little as $25 per monthly dose up to a monthly savings cap; maximum savings of $25,000 per 12-month enrollment period; card expires at the end of each calendar year.
- Applies to:
- Cyramza
- Number of uses:
- 12 times within calendar year
- Expires
- December 31, 2025
Form more information phone: 866-472-8663 or Visit website
Patient Assistance & Copay Programs for Cyramza
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Cyramza (ramucirumab) Injection; IV
More information please phone: 866-316-7263 Visit Website
Provider: Lilly Cares Foundation Patient Assistance Program
Eligibility requirements:- Contact program for details.
- Varies
- Not specified
- The patient must also be residing in the US.
- Please visit www.LillyCares.com or call (800) 545-6962 for more information. Additional products may be available. Please contact the program for a complete product listing. Lilly donates products to the Lilly Cares Foundation Patient Assistance Program.
- Cyramza (ramucirumab) Injection; IV
More information please phone: 800-545-6962 Visit Website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
More about Cyramza (ramucirumab)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: VEGF/VEGFR inhibitors
- Breastfeeding
- En español